Book a demo

Chemical intelligence powered by cypris.ai

5-Aza-1-(2-deoxy-beta-D-ribofuranosyl)cytosine

4-amino-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one

FormulaC8H12N4O4
Mol. weight228.208
PubChem CID24848394
InChIKeyXAUDJQYHKZQPEU-YSLANXFLSA-N
SMILESC1[C@@H](O[C@@H](C1O)CO)N2C=NC(=NC2=O)N
750Patents
113Research papers
73Patents - last 3 years
0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Celgene Corp25
2Massachusetts Institute of Technology25
3Astex Therapeutics Ltd21
4Institut National de la Santé et de la Recherche Médicale20
5German Cancer Research Center19
6The Brigham and Women's Hospital Inc17
7The University of Texas System15
8University of Southern California14
9Harvard University13
10The University of Texas at Austin13

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61PTherapeutic activity (drug indications)522
2A61KMedicinal preparations511
3C12NMicroorganisms, enzymes205
4C12QMeasuring/testing involving enzymes188
5C07KPeptides164
6G01NInvestigating / analysing materials121
7C07DHeterocyclic compounds82
8C07HSugars and derivatives82
9C12YEnzyme nomenclature (EC numbers)36
10Y02AClimate change adaptation34

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Epigenetics and DNA Methylation1
2HIV Research and Treatment1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1James G. HermanJohns Hopkins University4
2Chung S. YangRutgers, The State University of New Jersey3
3Gunn Iren MelingUniversity of Oslo3
4Guro E. LindNorwegian Cancer Society3
5John D. MinnaThe University of Texas Southwestern Medical Center3
6&NA;2
7Adi F. GazdarThe University of Texas Southwestern Medical Center2
8Andreas WahaUniversity of Bonn1
9Arend KochUniversity of Würzburg1
10Chang-Lai HaoInstitute of Hematology & Blood Diseases Hospital2

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the chemical composition of 5-Aza-1-(2-deoxy-beta-D-ribofuranosyl)cytosine?

5-Aza-1-(2-deoxy-beta-D-ribofuranosyl)cytosine has the molecular formula C8H12N4O4 with a molecular weight of 228.208. Its canonical name is 4-amino-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, and its InChI Key is XAUDJQYHKZQPEU-YSLANXFLSA-N.

Which organizations hold the most patents related to this compound?

Celgene Corp and Massachusetts Institute of Technology each hold 25 patents. Other leading patent holders include Astex Therapeutics Ltd with 21 patents, Institut National de la Santé et de la Recherche Médicale with 20 patents, and German Cancer Research Center with 19 patents.

What are the primary patent classification areas for this compound?

The compound is primarily classified under A61P (pharmaceutical preparations) with 522 patents and A61K (medicinal preparations) with 511 patents. Other significant classifications include C12N (biochemistry and microorganisms) with 205 patents and C12Q (measuring or testing processes involving enzymes or microorganisms) with 188 patents.

What research topics are associated with published papers on this compound?

Published papers on this compound cover Epigenetics and DNA Methylation and HIV Research and Treatment topics. Notable papers include work on modes of action of DNA methyltransferase inhibitors, strategies for reversing drug resistance, and epigenetic reprogramming mechanisms.

How has patent activity for this compound trended in recent years?

Patent activity peaked in 2016 with 46 patents and 2017 with 45 patents. In the last three years covered (2022–2024), patent counts were 34, 41, and 35 respectively. Overall, 73 patents related to this compound were filed in the last 3 years.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial